Recombinant Human soluble Tumor Necrosis Factor-Related Apoptosis-inducing Ligand Receptor-2/TNFRSF10B

Catalog No: #AP60043

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Package Size: #AP60043-1 10ug #AP60043-2 100ug #AP60043-3 500ug

Description

Product Name	Recombinant Human soluble Tumor Necrosis Factor-Related Apoptosis-inducing Ligand Receptor-2/TNFRSF10B
Host Species	Escherichia coli.
Purification	> 97 % by SDS-PAGE and HPLC analyses.
Other Names	soluble TRAIL Receptor-2, DR5, TNFRSF10B, KILER, TRICK2A, TRICKB
Calculated MW	Approximately 14.8 kDa, a single non-glycosylated polypeptide chain containing 132 amino acids.
Target Sequence	ESALITQQDL APQQRAAPQQ KRSSPSEGLC PPGHHISEDG RDCISCKYGQ DYSTHWNDLL FCLRCTRCDS GEVELSPCTT TRNTVCQCEE GTFREEDSPE MCRKCRTGCP RGMVKVGDCT PWSDIECVHK ES
Formulation	Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Images



Background

Tumor necrosis factor-related apoptosis-inducing ligand Receptor 2 (TRAIL-R2) is a cell-surface receptor involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling. The death ligand TRAIL bears high potential as a new anticancer agent, as binding to the death receptors TRAIL-R1 or TRAIL-R2 triggers apoptosis in most cancer cells. TRAIL-R2 has been shown to be associated with a decrease in the survival rates of breast cancer patients.

Note: This product is for in vitro research use only and is not intended for use in humans or animals.